Progress in Schizophrenia Research and Treatment

Keepers G, Fochtmann L, Anzia J, et al.: Guideline Writing Group. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. 2020 American Psychiatric Association. https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelinesGoogle Scholar

Taipale H, Lähteenvuo M, Tanskanen A, et al.: Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia. Schizophr Bull, in pressGoogle Scholar

Bowie CR, Bell MD, Fiszdon JM, et al.: Cognitive remediation for schizophrenia: an expert working group white paper on core techniques. Schizophr Res 2020; 215:49–53Crossref, Google Scholar

Goldsmith DR, Rapaport MH: Inflammation and negative symptoms of schizophrenia: implications for reward processing and motivational deficits. Front Psychiatry 2020; 11:46Crossref, Google Scholar

Ostuzzi G, Papola D, Gastaldon C, et al.: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Med 2020; 18:215Crossref, Google Scholar

Potkin SG, Kane JM, Correll CU, et al.: The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr 2020; 6:1Crossref, Google Scholar

Buchanan A, Sint K, Swanson J, et al.: Correlates of future violence in people being treated for schizophrenia. Am J Psychiatry 2019; 176:694–701Crossref, Google Scholar

Cella M, Wykes T: The nuts and bolts of cognitive remediation: exploring how different training components relate to cognitive and functional gains. Schizophr Res 2019; 203:12–16Crossref, Google Scholar

Faden J, Citrome L: Resistance is not futile: treatment-refractory schizophrenia—overview, evaluation and treatment. Expert Opin Pharmacother 2019; 20:11–24Crossref, Google Scholar

Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al.: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. (published correction appears in Lancet. 2019 Sep 14;394(10202:918) Lancet 2019; 394:939–951Crossref, Google Scholar

Iasevoli F, De Luca V, Nucifora FC: Editorial: neurobiology, clinical course, and therapeutic approaches of treatment-resistant schizophrenia: toward an integrated view. Front Psychiatry 2019; 10:870Crossref, Google Scholar

Lean M, Fornells-Ambrojo M, Milton A, et al.: Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2019; 214:260–268Crossref, Google Scholar

Marder SR, Cannon TD: Schizophrenia. N Engl J Med 2019; 381:1753–1761Crossref, Google Scholar

Roerig JL: Clozapine augmentation strategies. Ment Health Clin 2019; 9:336–348Crossref, Google Scholar

Smith RC, Leucht S, Davis JM: Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl) 2019; 236:545–559Crossref, Google Scholar

Tiihonen J, Taipale H, Mehtälä J, et al.: Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019; 76:499–507Crossref, Google Scholar

Cassidy RM, Yang F, Kapczinski F, et al.: Risk factors for suicidality in patients with schizophrenia: a systematic review, meta-analysis, and meta-regression of 96 studies. Schizophr Bull 2018; 44:787–797Crossref, Google Scholar

Dondé C, Vignaud P, Poulet E, et al.: Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand 2018; 138:289–299Crossref, Google Scholar

Girgis RR, Ciarleglio A, Choo T, et al.: A randomized, double-blind, placebo-controlled clinical trial of tocilizuamb, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 2018; 43:1317–1323Crossref, Google Scholar

Harvey PD, McGurk SR, Mahncke H, et al.: Controversies in computerized cognitive training. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3:907–915Crossref, Google Scholar

Ijaz S, Bolea B, Davies S, et al.: Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry 2018; 18:275Crossref, Google Scholar

Kesby JP, Eyles DW, McGrath JJ, et al.: Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry 2018; 8:30Crossref, Google Scholar

Krynicki CR, Upthegrove R, Deakin JFW, et al.: The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand 2018; 137:380–390Crossref, Google Scholar

Pringsheim T, Gardner D, Addington D, et al.: The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry 2018; 63:719–729Crossref, Google Scholar

Radua J, Ramella-Cravaro V, Ioannidis JPA, et al.: What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018; 17:49–66Crossref, Google Scholar

Taipale H, Mehtälä J, Tanskanen A, et al.: Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia—a nationwide study with 20-year follow-up. Schizophr Bull 2018; 44:1381–1387Crossref, Google Scholar

Correll CU, Rubio JM, Inczedy-Farkas G, et al.: Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74:675–684Crossref, Google Scholar

Fusar-Poli P, McGorry PD, Kane JM: Improving outcomes of first-episode psychosis: an overview. World Psychiatry 2017; 16:251–265Crossref, Google Scholar

Goff DC, Falkai P, Fleischhacker WW, et al.: The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 2017; 174:840–849Crossref, Google Scholar

Howells FM, Kingdon DG, Baldwin DS: Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Hum Psychopharmacol 2017; 32Crossref, Google Scholar

Howes OD, McCutcheon R, Agid O, et al.: Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 2017; 174:216–229Crossref, Google Scholar

Marder SR, Galderisi S: The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017; 16:14–24Crossref, Google Scholar

McDonagh MS, Dana T, Selph S, et al.: Treatments for schizophrenia in adults: a systematic review. comparative effectiveness review no. 198. AHRQ pub no. 17(18)-EHC031-EF. Rockville, MD, Agency for Healthcare Research and Quality, Oct 2017. https://effectivehealthcare.ahrq.gov/topics/schizophrenia-adult/research-2017.Google Scholar

Miyaoka T, Wake R, Hashioka S, et al.: Remission of psychosis in treatment-resistant schizophrenia following bone marrow transplantation: a case report. Front Psychiatry 2017; 8:174Crossref, Google Scholar

Wimberley T, MacCabe JH, Laursen TM, et al.: Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174:990–998Crossref, Google Scholar

Citrome L, McEvoy JP, Saklad SR: Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 2016; 10:163–177Crossref, Google Scholar

Dixon LB, Holoshitz Y, Nossel I: Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry 2016; 15:13–20Crossref, Google Scholar

Helfer B, Samara MT, Huhn M, et al.: efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016; 173:876–886Crossref, Google Scholar

Miller BJ, Dias JK, Lemos HP, et al.: An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry 2016; 77:275–276Crossref, Google Scholar

Sekar A, Bialas AR, de Rivera H, et al.: Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530:177–183Crossref, Google Scholar

Stroup TS, Gerhard T, Crystal S, et al.: Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016; 173:166–173Crossref, Google Scholar

Weiden PJ: Beyond psychopharmacology: emerging psychosocial interventions for core symptoms of schizophrenia. Focus 2016; 14:315–327Link, Google Scholar

Czobor P, Van Dorn RA, Citrome L, et al.: Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015; 25:1158–1166Crossref, Google Scholar

Najjar S, Pearlman DM: Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 2015; 161:102–112Crossref, Google Scholar

Petrides G, Malur C, Braga RJ, et al.: Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 2015; 172:52–58Crossref, Google Scholar

Sommer IE, van Bekkum DW, Klein H, et al.: Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling. Bone Marrow Transplant 2015; 50:153–154Crossref, Google Scholar

Benros ME, Nielsen PR, Nordentoft M, et al.: Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168:1303–1310Crossref, Google Scholar

Borgwardt SJ, Dickey C, Hulshoff Pol H, et al.: Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) All-Day Satellite, Scottsdale, Arizona. The Rapporteurs’ Report. Schizophr Res 2009; 112:32–45Crossref, Google Scholar

Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167:261–280Crossref, Google Scholar

Burns AM, Erickson DH, Brenner CA: Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr Serv 2014; 65:874–880Link, Google Scholar

Cella M, Bishara AJ, Medin E, et al.: Identifying cognitive remediation change through computational modelling--effects on reinforcement learning in schizophrenia. Schizophr Bull 2014; 40:1422–1432Crossref, Google Scholar

Correll CU, Rummel-Kluge C, Corves C, et al.: Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35:443–457Crossref, Google Scholar

Gallego JA, Nielsen J, De Hert M, et al.: Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11:527–542Crossref, Google Scholar

Howes OD, Murray RM: Schizophrenia: an integrated sociodevelopmental–cognitive model. Lancet 2014; 383:1677–1687Crossref, Google Scholar

Sommer IE, van Westrhenen R, Begemann MJ, et al.: Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014; 40:181–191Crossref, Google Scholar

Turner DT, van der Gaag M, Karyotaki E, et al.: Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry 2014; 171:523–538Crossref, Google Scholar

Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al.: Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA 2009; 106:1279–1284Crossref, Google Scholar